Broadcom vs. Taiwan Semiconductor: Which AI Chip Giant Is the Better Buy Right Now?

Broadcom's AI semiconductor revenue jumped 106% year over year to $8.4 billion in fiscal Q1 2026, with management guiding to about $10.7 billion in AI chip sales next quarter and signaling more than $100 billion of AI chip revenue by 2027. Taiwan Semiconductor also posted strong results, with revenue up 40.6% to $35.9 billion and its high-performance computing business rising to 61% of sales, while full-year 2026 revenue growth guidance was raised to more than 30%. The article is broadly constructive on both AI chip names, though it argues Broadcom has the stronger growth visibility despite a richer valuation and customer concentration risk.

Analysis

The market is increasingly treating AI spend as a two-layer stack: Broadcom monetizes the custom silicon layer with higher incremental revenue visibility, while TSM monetizes the manufacturing layer with broader but less concentrated capture. That distinction matters because custom accelerators and networking have the highest marginal value capture per AI dollar; if hyperscalers keep shifting away from merchant GPUs toward bespoke architectures, AVGO’s attach rate should keep compounding faster than the broader semiconductor complex. The implication is second-order negative for generic server silicon and certain interface-chip vendors, while still leaving NVDA structurally important at the training frontier.

TSM’s real leverage is not just unit growth but pricing power in the leading-edge bottleneck. If AI/HPC remains above 60% of mix, utilization and node scarcity can keep gross margins elevated even if smartphones soften, but the stock becomes more sensitive to any digestion in hyperscaler capex because the mix is less diversified than headline revenue suggests. In other words, TSM is the cleaner way to express “AI infrastructure build-out continues,” but it is also the first place where a capex pause would show up in monthly data before it shows in consensus estimates.

The consensus seems to be underweighting how much of AVGO’s upside is tied to backlog conversion rather than new order growth. A $73 billion backlog with a handful of customers creates a near-term path dependency: if one or two hyperscalers reprioritize deployments, near-term upside can gap down sharply even though the multi-year thesis remains intact. That makes AVGO better for a months-to-years view than for a straight-line quarter-to-quarter trade; TSM is the lower-beta way to own the same AI capex trend with less single-customer concentration, but more geopolitical overhang.

The contrarian setup is that both names may be priced as if AI capex stays linear, when the more likely path is lumpy. If AI spending pauses for even one or two quarters, AVGO’s premium multiple should compress first because expectations are more stretched, while TSM may hold up better on valuation and diversification. The key catalyst to watch is not just earnings beats, but guidance language around 2026 order visibility and any signs of customer-specific demand concentration narrowing or widening.

Key Decisions for Investors

• Long AVGO / short TSM in a 3-6 month pair trade if you want the purer AI-beta expression; AVGO should outperform on accelerating backlog conversion, but size smaller because the multiple is more vulnerable to any capex hesitation.
• If already long semis, rotate part of the exposure from NVDA-beta into TSM on any pullback: TSM offers cleaner exposure to the AI foundry bottleneck with less product-cycle risk than accelerator names over the next 6-12 months.
• Sell 1-2 month out-of-the-money AVGO puts or structure a call spread rather than outright long stock; upside is tied to backlog confidence, but the near-term valuation reset risk is asymmetric if hyperscaler spend is debated.
• Use TSM as a hedge against an AI capex slowdown in merchant-semiconductor leaders: if the market starts discounting weaker broad demand, TSM should be more resilient than AVGO, especially over the next earnings season.
• Watch for a downside reversal signal in monthly TSM revenue or AVGO customer commentary; if either implies a 1-quarter digestion period, fade the group tactically and re-enter on better multiples.